Document Detail


Regression of left ventricular hypertrophy--a meta-analysis.
MedLine Citation:
PMID:  1347256     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Left ventricular hypertrophy (LVH) is an independent risk indicator of cardiovascular disease. Obtaining reversal of hypertension-induced cardiac hypertrophy seems to be a desirable objective of antihypertensive treatment. A total of 2,357 patients were included in a meta-analysis on the effect of antihypertensive pharmacological therapy on LVH. Overall left ventricular mass (LVM) was reduced by 11.9% (95% confidence interval (CI) 10.1-13.7) in parallel with a reduction of mean arterial pressure of 14.9% (CI 14.0 to 15.8). When evaluating the effect of first-line therapies on calculated LVM using the same formula for all studies, the absolute reductions in g were 44.7 (ACE-inhibitors), 22.8 (beta-blockers), 26.9 (calcium antagonists) and 21.4 (diuretics) when adjusted for differences between studies (ANCOVA). It can be concluded that effective antihypertensive therapy reduces LVM. ACE-inhibitors, beta-blockers and calcium antagonists reduce LVM by reducing wall hypertrophy, the effect of ACE-inhibitors being the most pronounced. Diuretics reduce LVM mainly through an effect on left ventricular inner diameter. How these effects affect prognosis is still an open question.
Authors:
B Dahlöf; K Pennert; L Hansson
Related Documents :
8540636 - Growth of the myocardial volumes of the individual cardiac segments in the rat embryo.
438006 - A model of the effects of respiration on left ventricular performance.
9746126 - Atherosclerosis and left ventricular hypertrophy: persisting problems in treated hypert...
10235106 - Echocardiographic evaluation of left ventricular diastolic function in chronic cor pulm...
3279926 - Dry lung syndrome after oligohydramnios.
8540636 - Growth of the myocardial volumes of the individual cardiac segments in the rat embryo.
Publication Detail:
Type:  Journal Article; Meta-Analysis    
Journal Detail:
Title:  Clinical and experimental hypertension. Part A, Theory and practice     Volume:  14     ISSN:  0730-0077     ISO Abbreviation:  Clin Exp Hypertens A     Publication Date:  1992  
Date Detail:
Created Date:  1992-04-09     Completed Date:  1992-04-09     Revised Date:  2008-02-12    
Medline Journal Info:
Nlm Unique ID:  8207790     Medline TA:  Clin Exp Hypertens A     Country:  UNITED STATES    
Other Details:
Languages:  eng     Pagination:  173-80     Citation Subset:  IM    
Affiliation:
Department of Medicine, University of Göteborg, Ostra Hospital, Sweden.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Adrenergic beta-Antagonists / therapeutic use
Angiotensin-Converting Enzyme Inhibitors / therapeutic use
Antihypertensive Agents / therapeutic use
Calcium Channel Blockers / therapeutic use
Cardiomegaly / drug therapy*
Diuretics / therapeutic use
Humans
Meta-Analysis as Topic
Middle Aged
Chemical
Reg. No./Substance:
0/Adrenergic beta-Antagonists; 0/Angiotensin-Converting Enzyme Inhibitors; 0/Antihypertensive Agents; 0/Calcium Channel Blockers; 0/Diuretics

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Persistent measles virus infection enhances major histocompatibility complex class I expression and ...
Next Document:  The secondary prevention of myocardial infarction by drug treatment; excluding lipid lowering agents...